

COST-EFFECTIVENESS OF CURRENT PNEUMOCOCCAL VACCINES IN OLDER ADULTS IN EUROPEAN SETTINGS: A SYSTEMATIC LITERATURE REVIEW


Bhavsar A¹, Olbrecht J¹, Izurieta P¹
¹GSK, Wavre, Belgium

OBJECTIVES

- Currently, 23-valent pneumococcal polysaccharide vaccine (PPSV23) and 13-valent pneumococcal conjugate vaccine (PCV13) are available for use in older adults.
- Following the introduction of childhood pneumococcal immunization programs, substantial herd benefits among unvaccinated populations (including older adults) have been observed.¹⁻⁴
- However, due to serotype replacement, most of the serotypes affecting older adults are non-vaccine serotypes.² Adults with comorbidities are significantly more likely to suffer from community-acquired pneumonia from serotypes not covered by PCV13.⁵
- The objective of this systematic literature review was to summarize published cost-effectiveness analyses and recommendations for pneumococcal vaccines in adults ≥50 years of age in Europe.

METHODS

Figure 1: PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flow diagram of the systematic literature review



RESULTS







Figure 5: Recommendations for pneumococcal vaccination in ≥50-year-olds in European countries



References

1. Richter Id L, Schmid D, Kanitz EE, et al. PLoS One. 2019;14(1):e0210081. doi: 10.1371/journal.pone.0210081. 2. Ladhani SN, Collins S, Djennad A, et al. Lancet Infect Dis. 2018;18(4):441-451. doi: 10.1016/S1473-3099(18)30052-5. 3. Alari A, Chaussade H, Domenech De Cellès M, et al. BMC Med. 2016;14(1):211. doi: 10.1186/s12916-016-0755-7. 4. Bijlsma MW, Brouwer MC, Katanmoentalib ES, et al. Lancet Infect Dis. 2016;16(3):339-347. doi: 10.1016/S1473-3099(15)00430-2. 5. Daniel P, Rodrigo C, Bewick T, et al. Vaccine. 2018;36(12):1614-1620. doi: 10.1016/j.vaccine.2018.02.005. 6. Jiang Y, Gauthier A, Annemans L, et al. Expert Rev Pharmacoecon Outcomes Res. 2012;12(5):645-660. doi: 10.1586/erp.12.54. 7. Jiang Y, Gauthier A, Annemans L, et al. Value Health. 2011;14(7):A279. doi: 10.1016/j.jval.2011.08.260. 8. Kuhlmann A, Theidel U, Pletz MW, et al. Health Econ Rev. 2012;2(1):4. doi: 10.1186/2191-1991-2-4. 9. Rodríguez González-Moro JM, Menéndez R, Campins M, et al. Clin Drug Investig. 2016;36(1):41-53. doi: 10.1007/s40261-015-0345-z. 10. Thorington D, van Rossum L, Knol M, et al. PLoS One. 2018;13(2):e0192640. doi: 10.1371/journal.pone.0192640. 11. Willem L, Blommaert A, Hanquet G, et al. Hum Vaccin Immunother. 2018;14(5):1218-1229. doi: 10.1080/21645515.2018.1428507. 12. Mangen MJ, Rozenbaum MH, Huijts SM. Eur Respir J. 2015;46(5):1407-1416. doi: 10.1183/13993003.00325-2015. 13. Marbaix S, Peetermans WE, Verhaegen J, et al. PLoS One. 2018;13(7):e0199427. doi: 10.1371/journal.pone.0199427. 14. Blommaert A, Billec J, Willem L, et al. Vaccine. 2016;34(18):2106-2112. doi: 10.1016/j.vaccine.2016.03.003.

Disclosures
GlaxoSmithKline Biologicals SA funded this review and all costs related to the development of the publications. Authors would like to thank Business & Decision Life Sciences platform for editorial assistance and publications coordination, on behalf of GSK. Janne Tys and Gregory Leroux coordinated publications development and editorial support.

Presenting author:
Amit Bhavsar
amit.b.bhavsar@gsk.com

ISPOR-EU (2019) - 22nd Annual European Congress
2-6 November 2019 - Copenhagen, Denmark

